da Silva Jesse Lopes, de Paula Bruno Henrique Rala, Small Isabele Avila, Thuler Luiz Claudio Santos, de Melo Andréia Cristina
Clinical Research Division, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.
Breast Cancer (Auckl). 2020 Sep 25;14:1178223420962488. doi: 10.1177/1178223420962488. eCollection 2020.
To evaluate the association of sociodemographic, clinical, and pathological factors with response and survival in triple negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy (NACT).
Clinical-pathological and sociodemographic data were obtained from medical records of 235 eligible women with TNBC diagnosed between 2010 and 2014 undergoing NACT and surgery at the Brazilian National Cancer Institute. They have been assessed for pathological complete response (pCR), event-free survival (EFS), and overall survival (OS). Both univariate and multivariate Cox regression analyses were performed.
The median follow-up was 64.3 months. Most patients had advanced clinical stage (III: 85.1%; cT3/T4: 86.4%; cN1-3: 74.4%) and high-grade tumors (72.1%). Clinical staging (III vs II, adjusted hazard ratio [HR] = 2.95, = .012) significantly influenced the pCR rate. Alcohol intake negatively influenced EFS (adjusted HR = 1.67, = .006) and OS (adjusted HR = 1.89, = .005). Women with pCR showed better EFS (crude HR = 0.15, < .001) and OS (crude HR = 0.12, < .001) compared with non-pCR. The ypT (<0.001) and ypN (<0.001) gradually influenced survival outcomes.
Clinical stage III were associated with lower response rate and worse survival. Alcohol intake, pCR, and burden of post-NACT residual disease have shown considerable influence on survival outcomes.
评估社会人口统计学、临床和病理因素与接受新辅助化疗(NACT)的三阴性乳腺癌(TNBC)患者的反应及生存之间的关联。
从巴西国家癌症研究所2010年至2014年间诊断为TNBC并接受NACT及手术的235名符合条件的女性患者的病历中获取临床病理和社会人口统计学数据。对她们进行了病理完全缓解(pCR)、无事件生存期(EFS)和总生存期(OS)评估。进行了单因素和多因素Cox回归分析。
中位随访时间为64.3个月。大多数患者临床分期较晚(III期:85.1%;cT3/T4:86.4%;cN1 - 3:74.4%)且肿瘤分级高(72.1%)。临床分期(III期与II期,调整后风险比[HR]=2.95,P = 0.012)对pCR率有显著影响。饮酒对EFS(调整后HR = 1.67,P = 0.006)和OS(调整后HR = 1.89,P = 0.005)有负面影响。与未达到pCR的患者相比,达到pCR的女性显示出更好的EFS(粗HR = 0.15,P < 0.001)和OS(粗HR = 0.12,P < 0.001)。ypT(P < 0.001)和ypN(P < 0.001)逐渐影响生存结果。
临床III期与较低的反应率和较差的生存相关。饮酒、pCR以及NACT后残留疾病负担对生存结果有显著影响。